Hansoh Pharma's Innovative Drug Hengmu (Tenofovir Amibufenamide) Included as Preferred Treatment in China's 2022 Guidelines for Chronic Hepatitis B Management

On February 22, the Hepatology Society and Infectious Diseases Society of the Chinese Medical Association jointly released the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)" (hereinafter referred to as the "2022 Edition of the Chronic Hepatitis B Guidelines"). Hansoh Pharma's innovative drug, Hengmu (Amitinofivir Tablets, TMF), was included in the 2022 Edition of the Chronic Hepatitis B Guidelines due to its excellent efficacy and safety, and has been recommended as the first choice for antiviral treatment of chronic hepatitis B.

As an authoritative guideline in the field of chronic hepatitis B treatment in China, the 2022 edition of the Chronic Hepatitis B Guidelines was updated and revised based on the latest advances in basic and clinical research on chronic hepatitis B virus infection both domestically and internationally, taking into account the actual situation of chronic hepatitis B prevention and treatment in China. The new edition advocates more proactive screening and antiviral treatment, with updates covering multiple aspects such as prevention, indications, and treatment. It is of great value in standardizing the diagnosis and treatment practices of clinicians in the field of chronic hepatitis B in China and guiding clinical practice. The inclusion of Hengmu in the 2022 edition of the Chronic Hepatitis B Guidelines reflects the consistent recognition by the hepatology academic community of the clinical efficacy and safety of Hengmu.

Hengmu is the first China-developed oral anti-hepatitis B virus innovative drug independently researched and developed by Hansoh Pharma. Since its launch just over a year ago, it has successfully benefited more than 100,000 Chinese patients with chronic hepatitis B, providing clinicians with a better treatment option. The 96-week data from a large Phase III clinical study once again demonstrated Hengmu's higher efficacy, lower dosage, and enhanced safety as clinical advantages. Data shows that, compared with the existing first-line standard treatment drug Tenofovir Disoproxil Fumarate, Emtricitabine Tenofovir exhibits a comparable rate of virological suppression and a higher rate of ALT normalization. While ensuring effective anti-hepatitis B virus efficacy, Emtricitabine Tenofovir tablets also demonstrate superior bone and renal safety, making them an excellent choice for long-term medication in adult patients with chronic hepatitis B.

Reportedly, Hansoh Pharma will increase its R&D investment in the clinical research of Hengmu, extending the large-scale Phase III clinical study to ten years. The aim is to explore more application scenarios and evaluate the long-term efficacy and safety, continuously helping more patients with chronic hepatitis B improve their quality of life and return to normal living. (Zhu Wen)